Home › Companies › GRCE

Grace Therapeutics

GRCE Rare disease Lead: NDA Submitted 5 Biotech Distilled articles ↓

Neurology Small Molecule

Most recent annual filing: 2026-06-18

Pipeline (3 active programs)

nimodipine

GTx-104

Aneurysmal Subarachnoid Hemorrhage NDA Submitted intravenous

betamethasone

GTx-102

Ataxia Telangiectasia Phase 1 oral

bupivacaine

GTx-101

Postherpetic Neuralgia Phase 1 topical

Biotech Distilled coverage (5)

2026-06-18 UPDATE: Grace Therapeutics (GRCE) - The Pipeline Gets Euthanized and the Auditor Rings the Bell
2026-04-28 UPDATE: Grace Therapeutics (GRCE) - The CRL Autopsy and the Smart Money Exit 🔒 Paid
2026-04-24 UPDATE: Grace Therapeutics (GRCE) - The Silent Killer Strikes: Grace Gets a CRL 🔒 Paid
2026-02-14 UPDATE: Grace Therapeutics (GRCE) – The Float Shrinks as the Smart Money Parks for PDUFA 🔒 Paid
2026-01-26 Grace Therapeutics (GRCE): Scientific Deep Dive for GTx-104 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.